Initial immunogenicity results from BAL samples demonstrated that IV BCG resulted in a significant increase in the frequency of TB-specific CD4+ T-cells, and CD8+ T-cells compared to the other administration routes. The gene discussed is CD8A; the disease is tuberculosis.